One Stop Solution For In-Depth Market Research Reports


Home    >    HEALTHCARE AND PHARMACEUTICALS   >   Multiple Sclerosis Therapeutics Market

[ 英語タイトル ] Multiple Sclerosis Therapeutics Market - Growth, Trends, and Forecast (2020 - 2025)

Product Code : MDHC0084093
Survey : Mordor Intelligence
Publish On : November, 2020
Category : Healthcare and Pharmaceuticals
Study Area : Global
Report format : PDF
Sales price option (consumption tax not included)
Single User USD4250 / Question Form
5 User USD4750 / Question Form
Enterprise User USD7500 / Question Form
 - Teva Pharmaceuticals
- Novartis AG
- Pfizer Inc.
- Biogen Idec
- Bayer AG
- Sanofi S.A.
- Mylan N.V.
- Merck KGaA (Serono)
- F. Hoffmann-La Roche AG
- Acorda Therapeutics, Inc.

[Report Description]

The market studied is expected to witness rapid growth in the future owing to factors such as the rising prevalence of Multiple Sclerosis (MS) and the growing focus of companies on pipeline products for MS.

Big pharmaceutical companies are investing heavily in the drug development process and are planning to target as many indications as possible to cater to a large number of customers. Owing to this, the MS market is also getting benefited. For instance, drugs being developed for multiple sclerosis include the drugs for Relapsing-remitting MS, Secondary progressive MS, Primary progressive MS, and Myelin repair or neuroprotection. Biogen, a leading player in the market studied is developing Diroximel fumarate which is currently in phase III of development similarly Novartis is developing Ofatumumab which is also in Phase III.

Similar to the above-mentioned companies, there are other pharmaceutical players such as Pfizer Inc. that are developing drugs for MS. This indicate that pipeline drugs for MS will boost the market growth in the forecast period.

Key Market Trends

The Oral Route of Administration is Expected to Witness Rapid Growth in Future

Classical multiple sclerosis (MS) treatments using first-line injectable drugs, even though they are widely applied, remain to be a foremost concern in terms of therapeutic adherence and efficacy. Novel oral drugs, recently approved for the treatment of MS, represent significant advances in the therapy. The oral route of administration evidently supports patient satisfaction and increases therapeutic compliance.

If someone is not comfortable with needles, there are oral options for treating MS. Taken daily or twice daily, oral medications require one to maintain a regular dosing schedule. These are the easiest to be self-administered.

The currently available oral multiple sclerosis drugs include Aubagio (teriflunomide), Gilenya (fingolimod), and Tecfidera (dimethyl fumarate).

In March 2019, the US Food and Drug Administration approved Mayzent (siponimod) tablets to treat adults with relapsing forms of multiple sclerosis (MS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease..

North America to Dominate the Market

The market for Multiple Sclerosis Therapeutics is expected to show high growth in the North America region which is majorly attributed to the presence of key players and the rising prevalence of the disease in this region. United States is the major market for companies such as Biogen, Novartis AG, Sanofi SA, etc. Therefore, these companies focus more on establishing their new drugs in this market which ultimately contributes to the growth of this region.

Furthermore, as per the National Multiple Sclerosis Society, Canada is a country with the highest prevalence of MS in the world (291 per 100,000). In the case of the United States, the National MS Society estimated that there are around 1 million people in the country living with MS.

Hence, due to the high prevalence and presence of the key players, North America is expected to dominate the market.

Competitive Landscape

The market for MS therapeutics is consolidated as there are few players in this market. These companies are the big pharmaceutical companies that are currently focusing on pipeline drugs for multiple sclerosis. With the rising R&D investment in the pharmaceutical industry, it is believed that more companies will enter the market in the future and the competition will increase.

Reasons to Purchase this report:

- The market estimate (ME) sheet in Excel format
- 3 months of analyst support

1.1 Study Deliverables
1.2 Study Assumptions
1.3 Scope of the Study



4.1 Market Overview
4.2 Market Drivers
4.2.1 Raised Cases of Multiple Sclerosis Across the Globe
4.2.2 Growing Focus of Companies on Pipeline Products for MS
4.3 Market Restraints
4.3.1 Side Effects Associated with the Medication
4.3.2 High Cost of the Drugs
4.4 Porter's Five Force Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry

5.1 By Drug Type
5.1.1 Large-molecule Drugs
5.1.2 Small-molecule Drugs
5.2 By Route of Administration
5.2.1 Oral
5.2.2 Injectable and Others
5.3 Geography
5.3.1 North America United States Canada Mexico
5.3.2 Europe Germany United Kingdom France Italy Spain Rest of Europe
5.3.3 Asia Pacific China Japan India Australia South Korea Rest of Asia-Pacific
5.3.4 Middle East and Africa GCC South Africa Rest of Middle East and Africa
5.3.5 South America Brazil Argentina Rest of South America

6.1 Company Profiles
6.1.1 Teva Pharmaceuticals
6.1.2 Novartis AG
6.1.3 Pfizer Inc.
6.1.4 Biogen Idec
6.1.5 Bayer AG
6.1.6 Sanofi S.A.
6.1.7 Mylan N.V.
6.1.8 Merck KGaA (Serono)
6.1.9 F. Hoffmann-La Roche AG
6.1.10 Acorda Therapeutics, Inc.




Recommended reports